Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that its legal name has changed from Cybin Inc. to Helus Pharma Inc., effective Oct. 1, 2026. Shareholders approved the change at the company’s Sept. 22 annual and special meeting. The move follows the adoption of the Helus Pharma business name in January and reflects the company’s anticipated transition from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company.
The name change is more than a rebranding exercise; it signals Helus Pharma’s strategic shift toward commercialization. The company’s common shares will continue trading under the ticker HELP on the Nasdaq Global Market and Cboe Canada, with no action required by existing shareholders. This continuity is important for investors, as it ensures liquidity and visibility while the company advances its pipeline. For a deeper look at Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), the company’s relationship page provides additional details.
Helus Pharma, founded in 2019, is committed to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health. The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland.
The legal name change comes at a pivotal time for Helus Pharma. As it moves closer to potential commercialization, the new name may better reflect its evolved identity and ambitions. For investors, the change is largely procedural but underscores the company’s progress. The full press release is available at https://ibn.fm/rrJFh, and company updates can be found at www.helus.com.
The announcement was disseminated by MissionIR, a specialized communications platform that assists IR firms with syndicated content to enhance visibility of private and public companies. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution to millions of followers, and a full array of tailored corporate communications solutions. This infrastructure ensures that news like Helus Pharma’s name change reaches a wide audience of investors and stakeholders. For more information, visit www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website: https://www.MissionIR.com/Disclaimer.
